| Summary: | Lanadelumab is a human monoclonal antibody with a targeted mechanism of action that provides sustained inhibition of plasma kallikrein, which prevents the subsequent release of bradykinin and attacks of hereditary angioedema (HAE). It is indicated for the routine prevention of attacks of HAE in adolescents and adults aged 12 years or older. The recommended dose of lanadelumab is 300 mg administered via subcutaneous injection every two weeks. A dosage interval of 300 mg every four weeks may be considered if the patient's HAE is well-controlled or the patient has been attack-free for more than six months. Lanadelumab is supplied as a single ready-to-use (300 mg/2 mL) solution at a submitted price of $20,538 per vial. The average annual cost for lanadelumab is $533,988 and $266,994, with dosage intervals every two and four weeks, respectively. The manufacturer submitted a cost-utility analysis over a lifetime horizon (i.e., 60 years) from a Canadian publicly funded health care payer perspective
|
|---|